Long Non-Coding RNAs: Potential Biomarkers and Targets for Hepatocellular Carcinoma Therapy and Diagnosis

Donghong Yuan¹,²#, Yu Chen³#, Xiaobing Li¹#, Jing Li⁴, Yueshui Zhao¹,², Jing Shen¹,², Fukuan Du¹,², Parham Jabbarzadeh Kaboli¹,², Mingxing Li¹,², Xu Wu¹,², Huijiao Ji¹,², Chi Hin Cho¹,², Qinglian Wen²,⁵, Wanping Li¹*, Zhangang Xiao¹,²*, Bo Chen⁶*.

1. Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China
2. South Sichuan Institute of Translational Medicine, Luzhou, Sichuan, China
3. Department of Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China
4. Department of Oncology and Hematology, Hospital (T.C.M) Affiliated to Southwest Medical University, Luzhou, Sichuan, China
5. Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
6. Science and Technology Achievement Incubation Center, Kunming Medical University, Kunming, Yunnan, China

# These Authors Contributed Equally to This Work.
*Addresses for Correspondent Authors:

Wanping Li, Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China; E-mail: Wanping.Li@hotmail.com

Zhangang Xiao, Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China; E-mail: xzg555898@hotmail.com

Bo Chen, Science and Technology Achievement Incubation Center, Kunming Medical University, Kunming, Yunnan 650500, China; E-mail: chenbo@kmmu.edu.cn
Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. Increasing studies showed that long non-coding RNAs (lncRNAs), a novel class of RNAs that are greater than 200 nucleotides in length but lack the ability to encode proteins, exert crucial roles in the occurrence and progression of HCC. LncRNAs promote the proliferation, migration, invasion, autophagy, and apoptosis of tumor cells by regulating downstream target gene expression and cancer-related signaling pathways. Meanwhile, lncRNA can be used as biomarkers to predict the efficacy of HCC treatment strategies, such as surgery, radiotherapy, chemotherapy, and immunotherapy, and as a potential individualized tool for HCC diagnosis and treatment. In this review, we overview up-to-date findings on lncRNAs as potential biomarkers for HCC surgery, radiotherapy, chemotherapy resistance, target therapy, and immunotherapy, and discuss the potential clinical application of lncRNA as tools for HCC diagnosis and treatment.

Key Words

LncRNA; HCC; biomarkers; therapeutic and diagnostic targets.

Abbreviations

HCC, hepatocellular carcinoma; lncRNA, long non-coding RNA; LT, liver transplantation; LR, liver resection; HOTTIP, HOXA transcript at the distal tip; SNP, single nucleotide polymorphisms; MVIH, lncRNA associated with microvascular invasion in hepatocellular carcinoma; NEAT1, nuclear paraspeckle assembly transcript 1; OS, overall survival; MVI, microvascular invasion; MALAT1, metastasis associated lung adenocarcinoma transcript 1; HOTAIR, HOX transcript antisense RNA; EMT, epithelial-mesenchymal transition; linc-ROR, long noncoding RNA regulator of reprogramming; SUMO1P3, SUMO1 Pseudogene 3; H19, H19 imprinted maternally expressed transcript; lncRNA TP73-AS1, LncRNA P73 antisense RNA 1T; FU, fluorouracil; KARL, Keap1 regulation-associated lncRNA; CDDP, cisplatin; NRAL, Nrf2 regulation-associated lncRNA; TPTEP1, TPTE Pseudogene 1; NR2F1-AS1,
NR2F1 antisense RNA 1; HULC, Highly up-regulated in liver cancer; HANR, HCC associated long non-coding RNA; IncARSR, IncRNA regulator of akt signaling associated with HCC And RCC; RCC, renal cell carcinoma; SNHG1, small nucleolar RNA host gene 1; SNHG16, small nucleolar RNA host gene 16; SOR, sorafenib; SNHG3, small nucleolar RNA host gene 3; TUC338, transcribed ultra-conserved region 338; TIL, tumor infiltrated lymphocytes; Treg cells, T regulatory cells; AFP, alpha fetal protein; Inc-Tim-3, Inc-T cell immunoglobulin mucin 3; Inc- EGFR, Inc-epidermal growth factor receptor; FENDRR, fetal-lethal non-coding developmental regulatory RNA; Cox-2, cyclooxygenase-2; ROC, receiver operator characteristic; AUC, area under the curve; DCP, des-γ-carboxy prothrombin; LRB1, IncRNA uc007biz.1; UCA1, urothelial cancer associated 1; AAV, adeno-associated viral vector.

Introduction

Hepatocellular carcinoma (HCC), one of the primary liver cancers, ranks sixth in the incidence of global malignant tumors and ranks third in the mortality rate [1]. The occurrence of HCC is a complicated process caused by several factors. The main factors include chronic hepatitis viruses, and chronic hepatitis caused by heavy drinking, diabetes, and nonalcoholic fatty liver disease [2]. The treatment strategies for HCC proposed by clinical guidelines include tumor resection and liver transplantation by surgery, transhepatic arterial chemotherapy and embolization (TACE), and radiotherapy. Recent decades, new strategies, such as molecular targeting treatment, and immunotherapy, were applied for HCC treatment worldwide [3-5]. However, the impact of such improvement on population mortality from HCC is limited, since the five-year survival is still low [6]. Hence, early diagnosis, early treatment, and more effective treatment for HCC are particularly important.

Long non-coding RNAs (lncRNAs) are a class of RNAs with length longer than 200 nucleotides and lacking the ability to encode proteins [7]. Previous studies have suggested that non-coding RNAs are "transcriptional noise" production during gene expression, however, with the deepening of studies, researchers found that the proportion of non-coding genes in human genome is far more higher than the proportion
of protein-coding genes in human genome, which only accounts for less than 2% [8]. In recent years, with the development of high-throughput sequencing technologies, IncRNAs have been revealed to be abnormally expressed in tumor tissues. The abnormal expression of IncRNA is closely concerned with cancer occurrence, progression, and prognosis, and studies on IncRNAs brings new ideas for the study of the pathogenesis of tumor and for the exploration of new diagnostic and therapeutic methods (Figure 1) [9, 10]. More and more studies showed that IncRNAs, as oncogenes (Table 1) [11-56] or suppressors (Table 2) [57-76], play crucial role in regulating the progression, metastasis, and invasion of HCC.

In this review, we overview and discuss the up-to-date findings of the role of IncRNAs as potential diagnostic biomarkers and therapeutic targets for HCC diagnosis and treatment.

1. Serum LncRNAs as Potential Diagnostic Biomarkers for HCC

Serum alpha fetal protein (AFP) is the common and golden standard tumor biomarker for screening and diagnosing of HCC, however, recent studies showed that the sensitivity and specificity of using AFP as biomarker for early diagnosis of HCC are not satisfactory [77]. Novel biomarkers need to be searched for improving the early diagnosing rate of HCC. More and more studies showed that serum IncRNAs, such as ENSG00000258332.1, LINC00635, small nucleolar RNA host gene (SNHG)1, LncRNA uc007biz.1 (LRB1), highly up-regulated in liver cancer (HULC), linc00152, and urothelial cancer associated (UCA) 1 , are potential biomarkers for early diagnosis of HCC, meanwhile, combined detection of the serum levels of these IncRNAs with serum levels of AFP showed highest sensitivity and accuracy for early diagnosis of HCC [78-82].

Serum levels of several IncRNAs were upregulated in HCC patients. Xu et al. detected serum exosomes levels of LINC00635 and ENSG00000258332.1 in HCC patients, hepatic cirrhosis patients, chronic hepatitis B patients, and healthy subjects, and found that these IncRNAs were up-regulated in HCC group, and high serum levels of these IncRNAs are associated with poor prognosis [78]. Moreover, the combined
detection of serum levels of LINC00635, ENSG00000258332.1, and lAFP showed a high sensitivity for the diagnosis of HCC [78]. Gao et al. found that the plasma levels of lncRNA SNHG1 was higher in HCC patients [79]. Further investigation demonstrated that combined detection of SNHG1 and AFP levels improves the accuracy of the early diagnosis of HCC [79]. Similar study by Li et al. found that serum levels of HULC and Linc00152 were higher in HCC patients, and combined detection of serum levels of HULC, Linc00152, and AFP improves the diagnostic accuracy of HCC [80].

The upregulation of some lncRNAs also can be as potential biomarkers for diagnosing of HCC tumor stages and overall survival. Wang et al. found that the serum levels of LRB1, accompanied by the levels of protein markers AFP, were obviously increased in HCC patients, and using LRB1 combined with AFP as biomarkers can significantly improve the diagnostic accuracy of HCC [81]. Further investigation found that the serum LRB1 levels were positively correlated with HCC tumor stages, and were negatively associated with overall survival [81]. Zheng et al. found that UCA1, the serum levels of which was upregulated in HCC patient, is a good candidate marker for HCC diagnosis, and high serum UCA1 levels were correlated with advanced tumor, node, and metastasis (TNM) stage, high tumor grade, and high tumor size [82].

2. LncRNAs as Predictors for Recurrence and Survival Time after Surgical Treatment of HCC

Surgical treatments, including liver transplantation (LT) and partial liver resection (LR), are efficient methods for HCC treatment, however, the post-treatment prognosis remains poor due to metastasis and recurrence. Recent studies showed that lncRNAs have a great effect on the prediction of recurrence and survival time in HCC patients after surgery.

2.1 HOXA Transcript at the Distal Tip (HOTTIP)

Wu et al. collected blood and tumor tissue samples from 155 HCC patients who underwent LT treatment, the authors found that HOTTIP have a high expression level in HCC tissues [83]. COX multivariate analysis showed that high HOTTIP expression
was independent risk factor for tumor recurrence after LT and was associated with shorter overall survival time. Further in vitro studies indicated that down-regulated HOTTIP expression impairs the invasiveness and increases the chemosensitivity of tumor cells. In addition, two single nucleotide polymorphisms (SNPs) (rs2071265 and rs142077238) in the HOTTIP gene were genotyped in 102 peripheral blood samples of HCC patients, COX regression analysis found SNP rs2071265 is an independent predictor for HCC recurrence and is associated with early recurrence of HCC patients. These results indicate that HOTTIP expression levels and SNP type are predict indicator for tumor recurrence after liver transplantation in HCC patients [83].

2.2 IncRNA Associated with Microvascular Invasion in Hepatocellular Carcinoma (MVIH)

Yuan et al. found that the MVIH expression levels were markedly upregulated in cancer tissues of HCC patients undergoing hepatectomy [84]. Further analyses demonstrated that patients with higher MVIH expression levels showed worse relapse-free survival and overall survival, and higher MVIH expression level was a risk factor for early postoperative recurrence in HCC patients [84].

2.3 Nuclear Paraspeckle Assembly Transcript 1 (NEAT1)

NEAT1 is oncogenic IncRNA in diverse kinds of tumorigenesis, including gastric cancer, breast cancer, lung cancer and colorectal cancer [85]. Recent studies showed that NEAT1 can be used as an indicator of outcome evaluation in patients with HCC after tumor resection. Zhao et al. examined the expression level of NEAT1 in the liver cancer tissues of 86 primary liver cancer patients undergoing liver cancer resection, they found that NEAT1 expression was up-regulated in liver cancer tissues, and silencing NEAT1 arrested HCC cell proliferation, NEAT1 expression level is correlated with overall survival rate, microvessel formation-related invasion (MVI) and TNM stage [86].

2.4 Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1)

MALAT1 is the most widely researched IncRNAs in the treatment of cancer [87]. Studies have shown that the higher expression of MALAT1 is closely associated with
the progression and prognosis of patients with HCC. Lai et al. found that MALAT1 was upregulated in HCC tissues of patients undergoing liver transplantation, in comparison to the matched adjacent tissues. Further studies demonstrated that patients with high MALAT1 expression showed significantly lower recurrence survival rate than patients with low MALAT1 expression. In addition, multiple regression analysis showed that the expression level of MALAT1 could be used as a new independent predictor of recurrence-free survival after liver transplantation in patients with HCC [88].

2.5 HOX Transcript Antisense RNA (HOTAIR)

HOTAIR is the antisense strand of HOX gene cluster, and is an oncogenic lncRNA in cancer [89]. Yang et al. found that tumor tissues of HCC patients with LT showed high expression levels of HOTAIR [90]. Survival analyses revealed that 3-year cumulative recurrence-free survival rate of HCC patients with high expression of HOTAIR was enormously reduced, in addition, high levels of HOTAIR was also susceptible to early recurrence in patients with HCC undergoing surgical resection [90].

3. LncRNAs as Radiotherapy Biomarkers in HCC

Radiotherapy is one of the main traditional methods for HCC treatment [91]. Radiotherapy-resistant has become a main clinical problem for the successful treatment of HCC [92]. Recent studies demonstrated that aberrant expression of some kinds of lncRNAs are correlated with the development of HCC radioresistance (Figure 2).

3.1 Nuclear Paraspeckle Assembly Transcript1_2 (NEAT 1_2)

In HCC tissues and cells, Chen et al. found that the levels of lncRNA NEAT1_2 and oncogenic protein WEE1 was upregulated [93]. Knockdown of the expression levels of WEE1 and NEAT1_2 induced HCC cell apoptosis and enhances radiosensitivity. In addition, miR-101-3p was directly targeted to WEE1 and inhibited the WEE1 expression levels in HCC cells, while NEAT1_2 up-regulated the expression levels of WEE1 via sponge miR-101-3p. These studies indicate that NEAT1_2/miR-101-3p/WEE1 axis is a potential target signaling pathway for enhancing the sensitivity of HCC radiotherapy [93].

3.2 Long Noncoding RNA Regulator of Reprogramming (Linc-ROR)
Chen et al. investigated the roles of the linc-ROR in HCC, and found that linc-ROR promotes HCC metastasis by mediating epithelial-mesenchymal transition. Further study found that radiation-tolerant HCC cells showed higher levels of linc-ROR and lower levels of $\gamma$-H2AX, a DNA damage marker [94]. In addition, luciferase reporter assay showed that linc-ROR acts as a molecular sponge of miR-145 in HCC cells, and overexpression of linc-ROR can inhibit miR-145 expression and reduce translational inhibition of downstream miR-145 target RAD18, which is an important DNA repair factor, and radioresistance mediator [95]. Linc-ROR modulates RAD18 expression by competitively sponging miR-145, thereby inducing radioresistance of HCC cells [96]. Therefore, Linc-ROR can be used as a biomarker and as a potential target for HCC radiotherapy.

3.3 SUMO1 Pseudogene 3 (SUMO1P3)

SUMO1P3 is a novel identified IncRNA that was up-regulated in several types of cancer, including gastric cancer, bladder cancer, and non-small cell lung cancer, and is a prognostic and therapeutic target these cancers [97-99]. Zhou et al. explored the effect of SUMO1P3 in HCC, and discovered that the expression of SUMO1P3 was markedly increased in HCC tissues and cells [100]. In vitro, knockdown of SUMO1P3 expression of HCC cells, and explosion of these cells to radiation could significantly reduce the survival rates of HCC cells, indicating that knockdown of SUMO1P3 promotes the radiosensitivity of HCC cells. Meanwhile, knockdown of SUMO1P3 could also inhibit the growth of tumor cells, reduce invasiveness and promote apoptosis [100].

3.4 H19 Imprinted Maternally Expressed Transcript (H19)

LncRNA H19 was firstly identified as mammalian development regulator [101], and is an oncogenic IncRNA in cancers, including HCC [102]. Ma et al. found that the H19 expression level in radiation-sensitive HCC cells was obviously lower than that in radiation-resistant HCC cells [103]. Suppression of IncRNA H19 expression promotes radiation induced HCC cell apoptosis. Mechanistic studies demonstrated that IncRNA H19 directly targeted miR-193a-3p to suppress radiation induced HCC apoptosis [103]. Furthermore, PSEN1 can be directly targeted by miR-193a-3p, low expression of
PSEN1 was negatively related to radiosensitivity of HCC cells, so the H19/miR-193a-3p/ PSEN1 axis can be used as a potential pathway to ameliorate the curative effect of radio-therapies for HCC [103].

3.5 LINC00473

Zhang and colleagues detected the expression level of LINC00473 in HCC cell lines and normal hepatocytes, and the results indicated that the expression level of LINC00473 in HCC cell lines was significantly higher than that of normal hepatocytes [104]. Subsequently, SK-HEP-1 and Huh-7 cells were exposed to a gradient dose of radiation for 6 hours and then measured the level of LINC00473 again. The results showed that when the radiation dose reached 6 Gy, LINC00473 expression level was proportional to the radiation time. Further experiments found that knocking down LINC00473 inhibited the proliferation of HCC cells, induced apoptosis, and increased its radiosensitivity [104]. In terms of mechanism research, it was discovered that LINC00473 targets and inhibits the expression of miR-345-5p, and the overexpression of miR-345-5p can enhance the radiosensitivity of HCC cells [104]. Subsequent studies demonstrated that miR-345-5p negatively regulates forkhead box P1 (FOXP1), and silencing the FOXP1 gene hindered HCC radioresistance. These data indicate that the LINC00473 /miR-345-5p/FOXP1 axis regulates HCC cell radioresistance [104].

3.6 LncRNA P73 Antisense RNA 1T (LncRNA TP73-AS1)

LncRNA TP73-AS1 is located on human chromosome 1p36 [105], many evidences have identified LncRNA TP73-AS1 as an oncogene of liver cells [106, 107]. Song and colleagues found that TP73-AS1 expression was significantly increased in HCC cell lines and tissues [108]. In vitro studies showed that LncRNA TP73-AS1 down-regulated the expression of PTEN, enhanced the phosphorylation level of AKT, and reduced the radiosensitivity of HCC cells. The same results have also appeared in vivo experiments. After silencing LncRNA TP73-AS1, the tumor growth rate of mice was significantly slowed down, and the tumor volume was also significantly smaller than the control wildtype group [108].

4. LncRNAs and Chemotherapy Resistance in HCC
Chemotherapy is a traditional and efficient method for cancer therapy, the most common drugs for treating HCC include 5-fluorouracil (FU), cisplatin (CDDP), oxaliplatin, doxorubicin, gemcitabine, capecitabine, and mitoxantrone [109]. Although single or a combination of chemo drugs have proper effects on HCC, overtime use of chemotherapy for cancers can develop resistance to chemo-drugs, which greatly limits the efficacy of chemotherapy [110]. The molecular mechanism of chemotherapy resistance is related to apoptosis evasion, stem cell activation, enhanced DNA repair, and topoisomerase activation, these changes can promote drug inhibition, drug degradation, or drug target alteration, and finally help cancer cells to evade the effects of chemotherapy [111]. More and more investigations demonstrated that lncRNAs are new targets for the treatment of HCC drug resistance. In this part, we outline how lncRNAs participate in drug resistance of 5-FU, cisplatin, oxaliplatin, and doxorubicin in HCC (Figure 3).

4.1 5-FU Resistant-Related LncRNAs

4.1.1 Keap1 Regulation-Associated LncRNA (KRAL)

By performing lncRNA microarray analyses, Wu et al. found that the mRNA levels of KRAL were significantly reduced in 5-FU-resistant HCC cells [112]. Subsequent studies showed that KRAL inhibits Keap1 mRNA degradation by binding with the 3’-untranslated region (UTR) of Keap1 [113]. Keap1 is a potential mediator for drug sensitivity in cancer therapy by suppressing the activity of Nrf2 [114]. Previous studies have shown that miR-141 promotes Keap1 mRNA degradation [115], and the levels of miR-141 were significantly increased improved in SMMC-7721/5-FU and HepG2/5-FU cells5-FU-resistant HCC cells [113]. Moreover, miR-141 downregulates the expression of Keap1 by activating Nrf2-dependent antioxidant pathway to confer HCC cell resistance to 5-FU [113]. Therefore, the KRAL/miR-141/Keap1/Nrf2 axis pathway has potential great application prospects as a therapeutic target for overcoming HCC cells 5-FU resistance in HCC cells.

4.1.2 Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1)

LncRNA MALAT1 was initially identified as an indicator index of poor clinical
outcome in early-stage non-small cell lung cancer (NSCLC) patients [116]. As the study progressed, it was found that MALAT1 not only be useful for lung cancer but also has an essential effect on other human cancers, including HCC [117]. MALAT1 regulates tumor progression and metastasis by providing competitive endogenous RNA, interacting with polycomb repressive complex2 (PRC2) complexes, binding and inactivating TEAD, and regulating multiple signaling pathways [87, 118], also associated with cancer resistance [119, 120]. MALAT1 can be induced in tumor cells under hypoxic conditions[121], Yuan et al. first compared the expression of MALAT1 in 5-FU-sensitive and resistant HCC cell lines, and the results revealed that MALAT1 mRNA levels and the levels of hypoxia-inducible factor (HIF)-2α were significantly increased in 5-FU resistant cells [16]. Meanwhile, knockdown of HIF-2α in HCC cells abolished hypoxia-induced upregulation of MALAT1, these results indicate that HIF-2α promotes upregulation of MALAT1 in HCC cells [16]. Previous studies reported that enhanced autophagy is one of the chemical metabolism mechanisms of HCC cells [122, 123], and subsequent by performing bioinformatics analysis revealed that miR-216b is a potential MALAT1 target [16]. Further studies have shown that MALAT1 promotes autophagy by inhibiting the expression of miR-216b and enhances the 5-FU chemical metabolism in HCC cells [16].

4.2 Cisplatin (CDDP) Resistant-Related LncRNA

4.2.1 Nrf2 Regulation-Associated LncRNA (NRAL)

Wu et al. established the drug-resistant HCC cell lines and performed LncRNA microarray analysis to explore the expression patterns of LncRNAs in CDDP-resistant cancer cells [124]. Data showed that levels of NRAL in CDDP-resistant HCC cells was greatly upregulated [124]. Moreover, NRAL could bind with mir-340-5p, a tumor suppressor miRNA [125], to downregulate its expression. Further investigation showed that NRAL unites with miR-340-5p through endogenous "sponge", up-regulates its target Nrf2 expression, activates Nrf2-dependent antioxidant pathway leading to CDDP resistance in HCC cells [124]. The NRAL/miR-340-5p/Nrf2 axis may supply novel ideas for overcoming resistant to CDDP in HCC cells.
4.2.2 Growth Arrest Specific 5 and Cancer Susceptibility 2 (GAS5 and CASC2)

GAS5 was initially identified in a subtractive complementary DNA (cDNA) library, which was used to sequence RNA expressed in growth-arrested cells [126]. Subsequently, more and more literatures show that GAS5 plays a vital role in the progress of HCC [61-63]. Zhao et al. found that the expression of GAS5 in CDDP-resistant HCC patients and cell lines was significantly reduced, and the survival rate of HCC patients with low GAS5 expression was significantly decreased. Subsequent experimental results showed that overexpression of GAS5 increased the sensitivity of HepG2/CDDP and Huh7/CDDP cells to CDDP. In the mechanism study, it was found that GAS5 inhibited the expression of miR-222 gene, inactivating the VEGF signaling pathway and making CDDP-resistant HCC cells sensitive to CDDP [127]. In a recent study, it was found that another IncRNA CASC2 can also enhance the sensitivity of CDDP-resistant HCC cells to CDDP by inhibiting the expression of miR-222 gene [59].

4.2.3 LINC01234

LINC01234 has been proven to be an indicator of prognosis in ovarian cancer [128]. Yunhao Chen et al. analyzed the gene expression profiles of 374 HCC and 50 normal livers in the Cancer Genome Atlas database. They found that MAGEA3 and LINC01234 are both highly expressed in HCC tissues. Further analysis in the TargetScan database showed that MAGEA3 may be a downstream target of miR-31-5p. Next experiments confirmed that the down-regulation of MAGEA3 inhibits the proliferation and migration of HCC cells, induces apoptosis, and weakens the chemical resistance of HCC cells to cisplatin. Bioinformatics analysis suggests that LINC01234 can bind to miR-31-5p, further experiments found that miR-31-5p depletion can reverse the antitumor and chemosensitization caused by LINC01234 silence. These experiments confirmed that the reduction of LINC01234 up-regulated miR-31-5p, inhibiting the expression of MAGEA3, thereby increasing the chemical sensitivity of HCC cells to cisplatin [129].

4.2.4 TPTE Pseudogene 1 (TPTEP1)

TPTEP1 is located on chromosome 22 and is regulated by DNA methylation in
cancer [130]. Ding and colleagues used RNA-seq to analyze the differential expression of IncRNA in QGY7703 cells treated with cisplatin, and determined that IncRNA TPTEP1 had the highest expression level after cisplatin treatment [131]. Subsequent functional gain and loss experiments in liver cancer cell lines showed that the up-regulation of TPTEP1 inhibited the proliferation and invasion of HCC cells and enhanced the apoptosis induced by cisplatin, the opposite result appeared after silence TPTEP1 [131]. Further analyses found that TPTEP1 inhibits IL-6-induced phosphorylation of STAT3, thereby inhibiting the transcriptional activity of STAT3 and increasing the sensitivity of liver cancer cells to cisplatin. This result was also verified in in vivo experiments, TPTEP1 inhibited tumor growth in mice, reduced the number of lung and liver metastases, and was down-regulated in mouse tumor tissues [131].

4.3 Oxaliplatin Resistant-Related LncRNAs

4.3.1 NR2F1 Antisense RNA 1 (NR2F1-AS1)

Huang et al. performed microarray analysis on four pairs of oxaliplatin-resistant and sensitive HCC cells, and discovered that NR2F1-AS1 was highly expressed in oxaliplatin-resistant HCC cells [132]. Moreover, NR2F1-AS1 was also highly expressed in oxaliplatin-resistant HCC tissues [132]. knockdown NR2F1-AS1 inhibits HCC cell resistance to oxaliplatin, leading to suppress the migration, invasion and tumor growth of HCC cells [132]. NR2F1-AS1 mechanically induced HCC cell resistance to oxaliplatin by downregulating the expression of miR-363, which further induced high expression of multidrug resistance-associated protein 1 [132].

4.3.2 Highly Up-regulated in Liver Cancer (HULC)

HULC was first identified as the most up-regulated IncRNA in HCC [133]. Xiong et al. compared the levels of HULC in HCC tissues and corresponding adjacent non-cancerous liver tissues, and found that HULC mRNA and protein levels were significantly up-regulated in HCC tissues [134]. Increasingly evidence showed that HULC has a non-negligible role in the growth, invasion, migration, prognosis and chemoresistance of HCC [135]. Using a nude mouse xenograft model, investigators found that HULC knockdown significantly increased the sensitivity of oxaliplatin
chemotherapy, which may mediate by the stabilization of stress response gene sirtuin1 (sirt1) [134]. Sirt1 plays important roles in drug resistance by decreasing drug penetration [136], so the HULC-Sirt1 axis is a new target for overcoming resistance of HCC cells to chemotherapy drug oxaliplatin.

4.4 Doxorubicin Resistant-Related LncRNAs

4.4.1 HCC Associated Long Non-Coding RNA (HANR)

Xiao et al. found a novel lncRNA named as HCC associated long non-coding RNA (HANR), and found that the expression levels of HANR in HCC cell lines and HCC tissues were up-regulated. In addition, Kaplan-Meier analysis showed that high HANR expression was connected with poor prognosis [137]. Further studies showed that HCC cell resistance to doxorubicin is positively regulated by HANR [137]. HANR promotes HCC cells resistance to doxorubicin by regulating the activity of GSK3β [137], which plays important roles in drug-induced cancer cell apoptosis [138]. These findings indicate that HANR is a promising therapeutic target for HCC cell resistant to doxorubicin.

4.4.2 LncRNA Regulator of AKT Signaling Associated with HCC and RCC (LncARSR)

LncARSR was firstly found in renal cell carcinoma (RCC) cells, and had relations with resistance to sunitinib in RCC patients [139]. Li et al. found that LncARSR was significantly up-regulated in HCC tissues [140]. Further studies showed that overexpression of LncARSR significantly reduced the sensitivity of HCC cells to doxorubicin [140]. Moreover, knockdown of LncARSR rescues the sensitivity of HCC cells to doxorubicin treatment [140]. PTEN is a well-known tumor suppressor by inhibiting the activation of the PI3K/Akt pathway, and is associated with doxorubicin resistance in multiple cancers, including liver cancer [141]. Bioinformatics analysis and RNA pull-down experiment found that PTEN is a downstream target of LncARSR, and LncARSR negatively regulates PTEN expression in HCC tissues. Further investigations showed that PI3K/Akt pathway was involved in LncARSR-related doxorubicin resistance in HCC, as inhibition of PI3K/Akt pathway reversed LncARSR
overexpression-induced doxorubicin resistance [140]. These results indicate that lncARSR mediates doxorubicin resistance by downregulating the PTEN expression levels and subsequently reactivating PI3K/Akt signaling pathway [140].

5. LncRNAs and Targeted Therapy for HCC

Molecular targeted therapy is a new method for treating cancer that has been accepted by people in recent years. Many targeted drugs, including sorafenib (SOR), lenvatinib, regorafenib, cabozantinib, and ramucirumab, currently were used to treat HCC [142]. Sorafenib, as a first-line treatment for HCC, is particularly important for patients with advanced HCC and can improve the survival time of advanced hepatocellular carcinoma patients [143]. Sorafenib is an oral small-molecule multi-target tyrosine kinase inhibitor, and was approved for clinical treatment of HCC in 2007 [142]. Sorafenib can directly inhibit tumor proliferation, neovascularization, and promote apoptosis by inhibiting RAF/mitogen-active protein kinase/extracellular signal transduction pathways, vascular endothelial growth factor, PDGFRβ, c-kit, Flt-3 and p38 tyrosine kinase transfer, etc, [142]. However, many patients still develop acquired resistance to sorafenib. Recent studies have also reported that the development of sorafenib resistance involves many different pathways [144]. Emerging evidence indicates that multiple lncRNAs are involved in sorafenib resistance (Figure 3).

5.1 Small Nucleolar RNA Host Gene 1 (SNHG1)

SNHG1 is highly expressed in HepG2 and Huh7 cells [145], the study found that compared with untreated Huh7 cells, the SNHG1 level in the nuclear fraction of Huh7 cells incubated with sorafenib was significantly increased, indicating that sorafenib can cause nuclear accumulation of SNHG1 [145]. In addition, it has been reported that SNHG1 activates the Akt signaling pathway by promoting the transcription of SLC3A2 [146], and then by inhibiting the function of SNHG1, it was found that consumption of SNHG1 inhibits the activation of Akt signaling pathway and enhances the association with sorafenib resistance Apoptosis and autophagy [145], so SNHG1 may become a potential target for HCC treatment.

5.2 Small Nucleolar RNA Host Gene 1 (SNHG16)
LncRNA SNHG16 is a novel cancer-related lncRNA and promote tumor cell growth and metastasis in multiple cancers, including HCC cells and tissues [147]. Ye et al. found that the SNHG16 expression levels in SOR resistant HepG2 cells are higher than the levels in SOR sensitive HepG2 cells [147]. Further in vitro cell model and in vivo xenograft tumor model data showed that knockdown of SNHG16 enhanced SOR chemosensitivity in HCC [147]. In addition, SNHG16 promotes SOR resistance in HCC by inhibiting miR-140-5p the expression levels [147], which was found to promote the progression and metastasis of cancers [148].

5.3 Small Nucleolar RNA Host Gene 3 (SNHG3)

Zhang et al. found that the IC50 Value of SOR was significantly increased in SOR-treated SNHG3-overexpressing HCC cell, indicating that SNHG3 enhance SOR resistance [149]. In addition, data from patients with recurrent HCC who underwent sorafenib treatment showed that patients with higher SNHG3 expression had shorter median survival time than those with lower expression of SNHG3 [149]. Moreover, miR-128 was confirmed as potential target for SNHG3, and overexpression of miR-128 can reduce the level of CD151, which is rescued by increased expression of SNHG3 in HCC cells [149]. Previous studies have reported that CD151 activate PI3K/AKT signaling pathway to promote epithelial-mesenchymal transition (EMT) and SOR resistance [150], so SNHG3/miR-128/CD151 signaling can be used as a therapeutic target for HCC patients with SOR resistance.

5.4 Transcribed Ultra-Conserved Region 338 (TUC338)

LncRNA TUC338 was characterized as an oncogene in several types of cancer, such as prostate carcinoma and lung cancer [151, 152]. Ji et al. discovered that TUC338 was highly expressed in HCC cancer tissues and cell lines [153]. The knockdown of TUC338 significantly restores SOR treatment response in HepG2-SOR resistant cells in vitro and in HepG2-SOR resistant xenografts in vivo. Further in vitro study showed that knockdown of TUC338 upregulated the expression level of RAS GTPase activating protein (RasGAP) gene RASAL1 [153], which inhibits tumor progression by catalyzing RAS inactivation to negatively regulate the RAS signaling pathway [154].
5.5 Nuclear Paraspeckle Assembly Transcript 1 (NEAT1)

Chen et al. found that knockdown of NEAT1 promoted SOR-induced cancer cell death [155]. Bioinformatics analysis showed that NEAT1 can directly target miR-335, which suppresses the proliferation, migration of cancer cell [156], and subsequent in vitro experiment showed that overexpression of NEAT1 suppress the miR-335 expression in HCC cell lines [155], indicating that miR-335 is a downstream target of NEAT1. Moreover, miR-335 negatively regulate the expression of oncogene c-Met, and miR-335 inhibition or c-Met overexpression abolished NEAT1 knocking down-induced SOR sensitivity in HCC cells [155]. Overall, these data demonstrated that NEAT1/miR-335/c-Met axis regulates SOR resistance in HCC cells [155]. The same result was found in another study, NEAT1 regulates the miR-204/ATG3 axis and enhances the SOR resistance of HCC cells [157].

6. LncRNAs as Key Regulators for Immunotherapy of HCC

Immunotherapy has become one of the promising options for HCC treatment following surgery, radiotherapy, chemotherapy, and targeted therapy [158]. Recent studies highlighted the roles of lncRNAs in regulating immune system function in HCC by regulating T cell functions (Figure 4). In addition to the regulatory effect of lncRNA in T cells, it also affects macrophages and other immune cells. Tumor-associated macrophages (TAM) are important participants in tumor immunity, and the polarization of macrophages is one of the research hotspots in tumor therapy. M1 type macrophages have anti-tumor effects through direct killing mechanism and antibody-dependent cell-mediated cytotoxicity (ADCC) kills tumor cells [159]. Recent studies have found that lncRNA also plays a role in the polarization process of TAM.

6.1 LncRNA Associated with T cells in HCC

6.1.1 Nuclear Paraspeckle Assembly Transcript 1 (NEAT1)

Yan et al. found that expression levels NEAT1 were up-regulated in PBMC of HCC patients. Subsequent studies showed that knocking down of NEAT1 expression of CD8+ T cell suppressed cell apoptosis and enhanced the lytic activity to tumor cells by inhibiting Tim-3 expression [29]. Bioinformatics analyses and further in vitro studies
showed that miR-155 is a target of NEAT1, and miR155 inhibition alleviated knocking down of NEAT1-induced CD8+ T cell apoptosis, and rescued Tim-3 levels [29]. These results indicate that NEAT1/miR-155/Tim-3 pathway inhibits CD8+ T cell function and promotes HCC immune escape, which may act as a immunotherapy target for HCC patients [29].

6.1.2 Lnc-T Cell Immunoglobulin Mucin 3 (Lnc-Tim3)

Using high-throughput screening, Ji et al. explored the associations between mRNAs and lncRNAs in the tumor infiltrated lymphocytes (TIL) of HCC patients, and found that Lnc-Tim3 was highly up-regulated and negatively correlated with the IFN-γ-secreting activity of CD8+ T cells in TILs [54]. Further studies found that Lnc-Tim3 specific binding the intracellular domain of Tim-3 to inhibit T-cell immune response to antigen by suppressing downstream NFAT1/AP1 signaling pathway in CD8+ TILs, and binding of Lnc-Tim3 with Tim3 leads to release of Bat3 from Tim3, thereby promoting cell cycle arrest of CD8+ T cells, and contributing to the survival of CD8+ T cells [54]. These data suggest that lnc-Tim3 may affect the effectiveness of HCC immunotherapy by regulating the acquired immune system, mainly by regulating the activity of CD8+ T cells.

6.1.3 Lnc-Epidermal Growth Factor Receptor (Lnc-EGFR)

In order to prove the effect of lncRNAs in connecting T cells and HCC, Jiang et al. investigated the associations between mRNAs and lncRNAs in the tumor infiltrated lymphocytes (TILs) of patients with hepatocellular carcinoma and found that Lnc-EGFR levels in CD4+ T cells were highly up-regulated [55]. In addition, the expression of Lnc-EGFR in the CD4+ T cells correlated with increased proportion of T regulatory (Treg) cells within HCC tissues [55]. Further studies showed that Lnc-EGFR activates RAS/ERK/AP1/NF-AT1 signaling pathway to promote Treg cell differentiation [55]. It has been reported that Treg cells are related to HCC progression [160, 161], these results indicate that lnc-EGFR promotes immune escape of HCC by enhancing the differentiation of Treg cells.

6.1.4 Fetal-Lethal Non-coding Developmental Regulatory RNA (FENDRR)
Previous studies have shown that FENDRR down-regulates the expression of GPC3 and inhibits cell proliferation and migration [70]. In addition, FENDRR is also considered to be one of the potential markers for HCC diagnosis [162]. A recent study by Yu and colleagues found that FENDRR affects the immune escape of HCC cells. Based on microarray analysis, they discovered that the expression of FENDRR in HCC was low, and the results of qRT-PCR also showed that FENDRR was significantly lower in HCC tissues and cell lines than normal liver tissues [71]. Prediction by online tools showed that miR-423-5p and GADD45B have binding sites. The difference analysis between normal samples and HCC samples revealed that FENDRR and GADD45B are positively correlated, further research found that FENDRR can interact with miR-423-5p. Subsequent treatment of Tregs co-cultured with HCC cell lines with FENDRR and miR-423-5p mimics showed that FENDRR inhibited the immunosuppressive ability of Treg cells, while miR-423-5p mimics showed the opposite phenomenon. These results indicate that FENDRR competitively bind with miR-423-5p to up-regulate GADD45B, thereby inhibiting the immune escape of HCC cells mediated by Treg cells [71].

6.2 LncRNA Associated with Macrophages in HCC

6.2.1 LncRNA Cyclooxygenase-2 (Cox-2)

LncRNA Cox-2 is a lncRNA with a size of about 50 kb [163], it is reported that Cox-2 protein is an important metabolic regulator, which plays a role in biological processes such as development, mutation, cellular immunity and cancer [164-166]. The experiment of Ye et al. showed that lncRNA Cox-2 is highly expressed in M1 type macrophages, and silencing lncRNA Cox-2 inhibits the polarization of macrophages to M1 type, and enhances their ability to polarize to M2 type. Subsequently, the M1 macrophages after silencing the lncRNA Cox-2 gene were co-cultured with HCC cells, and the results suggested that the growth, invasion and migration, and immune escape capabilities of HCC cells were significantly enhanced. These results indicate that lncRNA Cox-2 inhibits the immune escape, invasion and migration of HCC cells by promoting the polarization of M1 macrophages [76].

6.2.2 TUC339
Previous studies have shown that lncRNA TUC339 is enriched in exosomes derived from HCC cells [167]. Li and his colleagues extracted exosomes from PLC/PRF/5 cells and incubated them with THP-1 cells for 24 hours, PLC/PRF/5-derived exosomes can be internalized by THP-1 cells. Further studies showed that PLC/PRF/5 exosomes were rich in TUC339, and hepatocellular carcinoma could deliver more TUC339 to adjacent THP-1 cells [56]. Subsequent studies showed that overexpression of TUC339 promotes M2-type polarization of macrophages, and inhibit M1-type polarization of macrophages. In general, TUC339 regulates macrophage phagocytosis and M1/M2 polarization, providing insights for tumor immunotherapy [56].

6.2.3 Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1)

Hou and colleagues found that after knocking out MALAT1 in HCC cell lines, the ability of macrophages to polarize toward the M1 subgroup was increased, while the ability to polarize toward the M2 subgroup was weakened [168]. Meanwhile, IL-6 expression level was increased while IL-10 expression level was decreased. Further study found that miR-140 is the target of MALAT1, and the expression level of miR-140 was significantly increased after MALAT1 was silenced. In addition, flow cytometry results showed that the silencing of MALAT1 increased the proportion of M1 subgroups, while miR-140 inhibitors reversed this effect [168]. The same results were obtained in vivo experiments. The M2 macrophages polarization ability was found to be significantly weakened in mice transplanted with heterotopic liver tumors of silenced MALAT1 gene. These results suggest that MALAT1 promotes the polarization of M2 macrophages through 466 miR-140 to produce anti-cancer effect [168].

7. Conclusion and Perspectives

The morbidity and mortality of HCC have been dramatically increased in recent decades. Despite advances in the diagnosis and treatment of HCC, effective treatment strategies were still not well, as metastasis and recurrence rate are still very high. More and more preclinical studies showed that lncRNAs are good diagnostic and prognostic biomarker candidates for HCC therapy. Although preclinical data showed strong relationship between lncRNAs and HCC, by now, no clinical studies were reported
about using lncRNAs as biomarkers for the diagnosis and prognosis of HCC. Future clinical studies may investigate the serum lncRNA profiles to explore more specific and sensitive lncRNA as biomarkers for HCC diagnosis and prognosis. To identify new lncRNAs as biomarkers for HCC, and to elucidate the molecular mechanisms of how lncRNAs work in HCC, future studies may need to focused on the development of experimental techniques, such as new sequencing techniques, and the development of lncRNA bioinformatics databases.

While lncRNAs have great potential in the diagnosis and prognosis of HCC, we also face a series of challenges when lncRNAs are used as a potential drug candidate or therapeutic target for HCC treatment. First, the molecular weight and negative charge of nucleic acids make it difficult to make lncRNAs pass through biofilms. Second, RNA is easily degraded by RNase enzymes in the human body, recognized by the immune system, and quickly eliminated by the liver and kidneys. Finally, it is easy to lose function in the endosomes. At present, there are two main methods to solve the delivery problem: one is to modify nucleic acid molecules to stabilize and avoid recognition by the immune system, the other is to use drug delivery systems, such as protamine vector technology, nanoparticle vector technology, adeno-associated viral vector (AAV) technology, etc., among which almost all natural AAV capsid proteins can trigger effective transgene expression in the liver, so recombinant AAV targeted to the liver is a treatment HCC provides an excellent gene delivery platform. However, these delivery systems still have defects such as immune system rejection and reduced protein expression efficiency, and future research should focus on developing novel methods to overcome these disadvantages.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Grant nos. 81602166, 81672444, and 81972643), the Science and Technology Strategic Cooperation Programs of Luzhou Municipal People’s Government and Southwest Medical University (Grant nos. 2019LZXNYDJ25, and 2019LZXNYDJ45), and by Special Fund of the Applied Basic Research Programs of Yunnan Province
associated with Kunming Medical University in China (grant no. 2018FE001(-193))

Author Contributions Statement

DY, YC, XL, JL, WL, ZX, and BC wrote the first draft of manuscript and first revision; YZ, JS, FD, BC, PK, ML, XW, HJ, CC, QW, WL, ZX, and BC revised the manuscript for second times before submission. All authors contributed to manuscript revision, read and approved the submitted version.

Conflicts of Interest

The authors declare that they have no conflict of interest.

References


37. Lin, Y.H., et al., Taurine up-regulated gene 1 functions as a master regulator to coordinate glycolysis and metastasis in hepatocellular carcinoma. Hepatology,


47. Huang, J.L., et al., *The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in*


57. Fan, J.C., et al., LncRNA CASC2 inhibited the viability and induced the


76. Ye, Y., et al., *Long non-coding RNA cox-2 prevents immune evasion and metastasis of hepatocellular carcinoma by altering M1/M2 macrophage*


86. Liu, Z., et al., Long non-coding RNA NEAT1 overexpression is associated with...


128. Guo, L., et al., *Expression profiles analysis reveals an integrated miRNA-lncRNA signature to predict survival in ovarian cancer patients with wild-type


139. Qu, L., et al., Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in


150. Ke, A.W., et al., CD151 amplifies signaling by integrin α6β1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells. Gastroenterology,


162. Mou, Y., et al., *Identification of long noncoding RNAs biomarkers in patients*


<table>
<thead>
<tr>
<th>Name</th>
<th>Genomic Location</th>
<th>Expression</th>
<th>Targets</th>
<th>Biological Functions in HCC</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>GHET1</td>
<td>7q36.1</td>
<td>Up</td>
<td>ATF1/ KLF2</td>
<td>Predict prognosis and promote tumorigenesis, proliferation.</td>
<td>[11, 12]</td>
</tr>
<tr>
<td>LASP1-AS</td>
<td>17q12</td>
<td>Up</td>
<td>LASP1</td>
<td>Promote tumorigenesis</td>
<td>[13]</td>
</tr>
<tr>
<td>MALAT1</td>
<td>11q13.1</td>
<td>Up</td>
<td>miR-30a-5p; miR-195/EGFR; miR-143-3p/ ZEB1; miR -216b /HIF -2a</td>
<td>Promote tumorigenesis, metastasis and progression. Promote chemotherapy resistance.</td>
<td>[14-18]</td>
</tr>
<tr>
<td>HULC</td>
<td>6p24.3</td>
<td>Up</td>
<td>miR-186/HMGA2; ERK/YB-1; Sirt1</td>
<td>Promote tumorigenesis, progression, metastasis and predict prognosis.</td>
<td>[19, 20]</td>
</tr>
<tr>
<td>HOTAIR</td>
<td>12q13.13</td>
<td>Up</td>
<td>EZH2/miR-122; miR-218/ Bmi-1; RNA binding motif protein 38; GLUT1/mTOR</td>
<td>Promote tumorigenesis, migration and invasion.</td>
<td>[21-24]</td>
</tr>
<tr>
<td>ZFAS1</td>
<td>20q13.13</td>
<td>Up</td>
<td>miR-150</td>
<td>Associate with tumor metastasis</td>
<td>[25]</td>
</tr>
<tr>
<td>NEAT1</td>
<td>11q13.1</td>
<td>Up</td>
<td>miR-139/TGF-β1; miR-485 / STAT3; MiR-384; miR-101-3p/WEE1;</td>
<td>Promote tumor progression and metastasis; Promote resistance to chemotherapy and radiothererapy</td>
<td>[26-28]</td>
</tr>
<tr>
<td>miRNA Cluster</td>
<td>Chromosomal Location</td>
<td>Expression Change</td>
<td>Associated Genes</td>
<td>Functions and Predicted Outcomes</td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>----------------------</td>
<td>------------------</td>
<td>-----------------</td>
<td>----------------------------------</td>
<td></td>
</tr>
<tr>
<td>miR-335-c-Met</td>
<td></td>
<td></td>
<td>miR-217/ MAPK1; miR-136-5P/ IRX5; Wnt/β-catenin</td>
<td>Associate with tumor proliferation, migration, invasion and EMT [30-32]</td>
<td></td>
</tr>
<tr>
<td>CRNDE</td>
<td>16q12.2</td>
<td>Up</td>
<td>let-7c/5p / NAP1L1</td>
<td>Promote tumor growth and metastasis [33]</td>
<td></td>
</tr>
<tr>
<td>TUG1</td>
<td>22q12.2</td>
<td>Up</td>
<td>miR-144 /AK2/ STAT3; miR-142-3p/ZEB1; KLF2</td>
<td>Promote tumor proliferation, migration, invasion and induce cell apoptosis [34-37]</td>
<td></td>
</tr>
<tr>
<td>PVT1</td>
<td>8q24.21</td>
<td>Up</td>
<td>miR-150/HIG2; EZH2 / miR-214</td>
<td>Promote tumor invasion, metastasis and predict prognosis [38-41]</td>
<td></td>
</tr>
<tr>
<td>ZNF667</td>
<td>19q13.43</td>
<td>Up</td>
<td>Bcl-2/BAX</td>
<td>Associate with tumor progression and inhibit apoptosis [42]</td>
<td></td>
</tr>
<tr>
<td>FAL1</td>
<td>Chromosome IV</td>
<td>Up</td>
<td>miR-1236</td>
<td>Promote tumor proliferation and migration, [43]</td>
<td></td>
</tr>
<tr>
<td>SNHG12</td>
<td>1p35.3</td>
<td>Up</td>
<td>miR-199a/b-5p</td>
<td>Promote tumorigenesis and metastasis [44]</td>
<td></td>
</tr>
<tr>
<td>SNHG8</td>
<td>4q26</td>
<td>Up</td>
<td>miR-149-5p</td>
<td>Promote tumorigenesis, metastasis and predict tumor recurrence [45]</td>
<td></td>
</tr>
<tr>
<td>FEZF1-AS1</td>
<td>7q31.32</td>
<td>Up</td>
<td>miR-4443</td>
<td>Contribute to tumor proliferation, migration and invasion [45]</td>
<td></td>
</tr>
<tr>
<td>SOX21-AS1</td>
<td>13q32.1</td>
<td>Up</td>
<td>p21</td>
<td>Associate with tumor progression and predict prognosis [46]</td>
<td></td>
</tr>
<tr>
<td>PTTG3P</td>
<td>8q13.1</td>
<td>Up</td>
<td>PTTG1/PI3K/AKT</td>
<td>Promote cell growth, metastasis and [47]</td>
<td></td>
</tr>
<tr>
<td>LncRNA</td>
<td>Chromosome</td>
<td>Expression</td>
<td>miRNA/Pathway</td>
<td>Function</td>
<td>Reference</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>------------</td>
<td>---------------</td>
<td>----------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>NORAD</td>
<td>20q11.23</td>
<td>Up</td>
<td>miR-202-5p/ TGF-β</td>
<td>Promote tumor progression</td>
<td>[48]</td>
</tr>
<tr>
<td>CASC11</td>
<td>8q24.21</td>
<td>Up</td>
<td>PTEN and PI3K/AKT</td>
<td>Promote tumor migration, invasion and EMT</td>
<td>[49]</td>
</tr>
<tr>
<td>SNHG5</td>
<td>6q14.3</td>
<td>Up</td>
<td>miR-26a-5p/GSK3β</td>
<td>Promote tumor progression</td>
<td>[50]</td>
</tr>
<tr>
<td>CCAT2</td>
<td>8q24.21</td>
<td>Up</td>
<td>NDRG1</td>
<td>promote tumor proliferation and metastasis</td>
<td>[51]</td>
</tr>
<tr>
<td>FOXD2-AS1</td>
<td>1p33</td>
<td>Up</td>
<td>DKK1 and Wnt/β-catenin</td>
<td>promote tumor progression and activate Wnt/β-catenin signaling pathway</td>
<td>[52, 169]</td>
</tr>
<tr>
<td>PAPAS</td>
<td>15q24.3</td>
<td>Up</td>
<td>miR-188-5p</td>
<td>promote tumor progression</td>
<td>[53]</td>
</tr>
<tr>
<td>Name</td>
<td>Genomic Location</td>
<td>Expression</td>
<td>Targets</td>
<td>Biological Functions in HCC</td>
<td>References</td>
</tr>
<tr>
<td>------</td>
<td>------------------</td>
<td>------------</td>
<td>---------</td>
<td>-----------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>CASC2</td>
<td>10q26.11</td>
<td>Down</td>
<td>miR-24-3p; miR-367/FBXW7; miR-362-5p/NF-kB</td>
<td>Inhibit tumor growth, migration, invasion and EMT</td>
<td>[57, 58, 60, 170]</td>
</tr>
<tr>
<td>DGCR5</td>
<td>22q11.21</td>
<td>Down</td>
<td>miR-346/KLF14; β-catenin/cyclin D1/GSK-3β</td>
<td>Inhibit tumor progression and associate with prognosis</td>
<td>[61-63]</td>
</tr>
<tr>
<td>MEG3</td>
<td>14q32.2</td>
<td>Down</td>
<td>miRNA-664/ADH4 p53</td>
<td>Inhibit tumor progression and associate with prognosis</td>
<td>[64, 65]</td>
</tr>
<tr>
<td>GAS5</td>
<td>17p13.3</td>
<td>Down</td>
<td>miR-135b/RECK/ MMP-2; miR-182/ANGPTL1; miR-21</td>
<td>Inhibit tumor proliferation, migration, invasion and induce cell apoptosis and associate with prognosis</td>
<td>[66-68]</td>
</tr>
<tr>
<td>MIR22HG</td>
<td>17p13.3</td>
<td>Down</td>
<td>miRNA-10a-5p / NCOR2</td>
<td>Inhibit tumor growth, migration, invasion and predict prognosis</td>
<td>[69]</td>
</tr>
<tr>
<td>FENDRR</td>
<td>12q13.13</td>
<td>Down</td>
<td>GPC3</td>
<td>Promote tumorigenesis, migration and invasion</td>
<td>[70]</td>
</tr>
<tr>
<td>HOTAI RM1</td>
<td>7p15.2</td>
<td>Down</td>
<td>Wnt</td>
<td>Inhibit tumor progression</td>
<td>[72]</td>
</tr>
<tr>
<td>AGI2-AS3</td>
<td>7q21.11</td>
<td>Down</td>
<td>miR-374b-5p/SMG1</td>
<td>Inhibit tumor proliferation and migration</td>
<td>[73]</td>
</tr>
<tr>
<td>NRON</td>
<td>9q33.3; 9</td>
<td>Down</td>
<td>interleukin-6/STAT3</td>
<td>suppresses tumor cell proliferation and metastasis</td>
<td>[74]</td>
</tr>
<tr>
<td>miR503HG</td>
<td>Xq26.3</td>
<td>Down</td>
<td>HNRNPA2B1/NF-κB</td>
<td>Inhibits tumor metastasis</td>
<td>[75]</td>
</tr>
</tbody>
</table>
Figure Legends:

Figure 1. Potential Clinical Applications of LncRNAs as Biomarkers for Diagnosis and Treatment of HCC.
LncRNAs can be used as an indicator to distinguish benign and malignant tumors. Serum LncRNAs can be used as potential biomarkers for HCC diagnosis, or be used as one of the reference conditions for clinicians to choose suitable therapeutic strategy. Continuous collection of blood samples and check the types and levels of serum LncRNA during treatment can be an important indicator of the effectiveness of treatment, as well as monitoring disease progression and predicting the prognosis of HCC patients.

Figure 2. LncRNAs as Radiotherapy Biomarkers in HCC.
Aberrant expression of LncRNAs associated with the development of HCC radioresistance, leading to metastasis and progression of HCC. LncRNAs mediate functions by regulating miRNA expression via diverse molecular mechanisms.

Figure 3. LncRNAs in Drug Resistance of HCC.
Up- or down-regulation of LncRNAs could enhance the resistance of HCC cells to various chemotherapeutic and targeted drugs, leading to tumor cell invasion, metastasis or the inhibition of cancer cell apoptosis.

Figure 4. LncRNA Regulates HCC Invasion and Progression by Modulating Tumor Immune Escape.
LncRNA promotes tumor immune escape in HCC. For example, NEAT1 inhibits the expression of miR-155 and increases the activity of Tim3, resulting in apoptosis of CD8⁺ T cells. Lnc-Tim3 inhibits NF-AT1 and AP1 signaling, thereby inducing CD8⁺ T cell failure. In addition, Lnc-EGFR activates the RAS/ERK/AP1/NF-AT1 signaling pathway to promote Treg cell differentiation, thereby contributing to tumor cell immune escape.
Serum lncRNA in tumor tissue

Distinguishing benign and malignant tumors

Liver tumor biopsy

Pretreatment blood sample

Serum lncRNA

Blood samples during treatment

Continuous detection of the types and levels of serum lncRNAs

Figure 1

Tumor diagnosis
Choosing therapy target

Monitoring treatment effects
Monitoring tumor progression
Evaluating patient prognosis
Figure 2

- NEAT1
  - miR-101-3p
    - WEE1

- linc-ROR
  - miR-145
    - RAD18

- H19
  - miR-193a-3p
    - PSEN1

- Radioresistance
  - FOXP1
    - miR-345-5p
      - LINC00473
  - p-AKT
    - PTEN
      - TP73-AS1

- Metastasis
  - Cancer Cell
  - Metastatic Cancer Cell
Figure 3

Invasion, Metastasis, Apoptotic Suppression, Oxaliplatin Resistance, Cisplatin Resistance, 5-FU Resistance, Doxorubicin Resistance, Sorafenib Resistance

- SNHG1
- SNHG16
- SLC3A2
- miR-140-5p
- NEAT1
- miR-335
- TUC338
- RASAL1
- CD151
- miR-128
- SNHG3
- HANR
- GSKIP
- GSK3β
- PI3K/AKT
- AR3R
- PTEN
- KRAL
- HIF-2
- MALAT1
- miR-141
- Nrf2
- miR-216b
- Autophagy
- mRN22
- P-STAT3
- MAGEA3
- IL-6
- NRAL
- VEGF
- GAS5
- CASC2
- LINC01234
Figure 4

Tim-3

Lnc-Tim3

Bat3

Inactive Lck

AP-1 NF-AT1

Damaged CD8+ T Cell

Lnc-EGFR

EGFR

Ub

FENDRR

NEAT1

IncRNA Cox-2

TUC339

MALAT1

miR-423-5p

miR-155

GADD45B

Tim-3

AP-1 NF-AT1

CD8+

Apoptotic CD8+ T Cell

M1 Macrophage Polarization

M2 Macrophage Polarization

Tumor Invasion and Progression